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Background: The Tanzanian Government started scaling up its antiretroviral treatment (ART) program from referral,
regional and district hospitals to primary health care facilities in October 2004. In 2010, most ART clinics were
decentralized to primary health facilities. ART coverage, i.e. people living with HIV (PLHIV) on combination treatment
as a proportion of those in need of treatment, provides the basis for evaluating the efficiency of ART programs at
national and district level. We aimed to evaluate adult ART and pre-ART care coverage by age and sex at CD4 < 200,
< 350 and all PLHIV in the Rufiji district of Tanzania from 2006 to 2010.
Methods: The numbers of people on ART and pre-ART care were obtained from routinely aggregated, patient-level,
cohort data from care and treatment centers in the district. We used ALPHA model to predict the number in need of
pre-ART care and ART by age and sex at CD4 < 200 and < 350.
Results: Adult ART coverage among PLHIV increased from 2.9% in 2006 to 17.6% in 2010. In 2010, coverage was 20%
for women and 14.8% for men. ART coverage was 30.2% and 38.7% in 2010 with reference to CD4 criteria of 350 and
200 respectively. In 2010, ART coverage was 0 and 3.4% among young people aged 15–19 and 20–24 respectively. ART
coverage among females aged 35–39 and 40–44 was 30.6 and 35% respectively in 2010. Adult pre-ART care coverage
for PLHIV of CD4 < 350 increased from 5% in 2006 to 37.7% in 2010. The age-sex coverage patterns for pre-ART care
were similar to ART coverage for both CD4 of 200 and 350 over the study period.
Conclusions: ART coverage in the Rufiji district is unevenly distributed and far from the universal coverage target of
80%, in particular among young men. The findings in 2010 are close to the most recent estimates of ART coverage in
2013. To strive for universal coverage, both the recruitment of new eligible individuals to pre-ART and ART and the
successful retention of those already on ART in the program need to be prioritized.
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In recognition of the positive impact of antiretroviral
treatment (ART) on HIV-associated survival, the
Tanzanian Government, in collaboration with inter-
national organizations and donor agencies, introduced
a treatment program in October 2004 aimed at treating
all eligible AIDS patient with antiretroviral drugs
(ARV) [1-5]. ART scale-up in Tanzania started in 2004* Correspondence: flevira@ihi.or.tz
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unless otherwise stated.with 96 care and treatment centers (CTC) which grew
to about 1100 in 2010 [6]. The number of PLHIV en-
rolled on ART was 23,951 in December 2005, reached
approximately 384,816 by 2010 [6,7]. AIDS-related
mortality and new HIV infection decreased by 41% and
46% between 2005 and 2013 respectively [8]. Recent
evidence shows in addition to treating AIDS patients,
ART is potential for preventing further spread of HIV
virus [9-11]. Slow progress in ART enrollment in many
countries in resource-limited setting prompted a polit-
ical declaration on HIV and AIDS in 2011 aimed at
“Intensifying efforts to eliminate HIV and AIDS andThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of universal access to comprehensive prevention, treat-
ment, care and support” [12,13]. Several global initiatives
followed the UN declaration includes “Treatment 2015”
aimed at reaching an estimated 15 million people with
antiretroviral therapy by 2015 [14] and “UNAIDS 90-90-
90” aimed to achieve the following by 2020; 90% of all
PLHIV know their HIV status, 90% of all people with diag-
nosed HIV infection receive sustained antiretroviral ther-
apy and 90% of all people receiving antiretroviral therapy
have viral suppression [15].
ART treatment coverage is one of the key indicators
used by program managers in assessing health system
performance and community engagement in treating
and preventing HIV. It is measured as PLHIV on com-
bination treatment as a proportion of those in need of
treatment [16]. The definition of the number of people
in need of ART has varied over the years with changes
in WHO guidelines (<200 CD4 in 2006, <350 in 2010
and <500 in 2013). Changes in the guidelines came as a
result of emerging evidence from clinical trials of im-
proved survival upon early ART initiation. In Tanzania,
an eligibility criterion of CD4 count < 200 was adopted
when the treatment program started in 2004 until
2012 when changes to adopt the 2010 World Health
Organization (WHO) guideline of CD4 < 350 were
made. An estimate from WHO showed adult coverage
was 49% under CD4 < 200 in 2006. Under CD4 < 350
adult ART coverage was 32% in 2009, 40% in 2011 and
68% in 2012 [16].
Evaluation of the efficiency of ART programs through
ART coverage has been hampered by a lack of reliable
statistics on who is on treatment and who is eligible for
treatment in most resource-limited countries. A substan-
tial proportion of PLHIV are not aware of their HIV
status and ART eligibility due to low HIV testing rates,
therefore the ideal number of those in need of treatment
cannot directly be obtained unless mathematical models
are applied. The absence of a comprehensive information
system to document exact number of PLHIV on treat-
ment, ART adherence, drop-out and mortality makes the
ART coverage estimation uncertain. UNAIDS developed
the Spectrum model, a constantly updated, user-friendly
software program which predicts the theoretical need
for ART at national level by projecting distribution of
expected CD4 counts and past HIV incidence in the
population among other parameters [17,18]. However,
some of the Spectrum’s model input parameters, such
as the distribution of CD4 counts and HIV incidence,
are rarely available at national and sub-national level
and may lead to less reliable estimates of treatment
coverage. This gap in valid program data, especially at
sub-national level such as district, may compromise
strategic priority and target settings in this era of powerdecentralization to the districts. So far, regional and dis-
trict level data have not been well utilized in generating
local level estimates of treatment coverage for district
level planning. Recently, UNAIDS used all PLHIV as the
denominator to calculate ART coverage. This is due to
the fact that national ART initiation guidelines do not
always match global guidelines, making country com-
parisons and time trend analysis of little value [19]. In
2013, UNAIDS estimated ART coverage for adults living
with HIV regardless of CD4 count in Tanzania to be
41% [8]. A review of ART initiation criteria in the
national guidelines for 94 countries (representing 86%
of global HIV burden) showed that only seven countries
from the developed world initiate ART irrespective of
CD4 cell count [10]. Alternative methods to estimate
the number of PLHIV in need of treatment for countries
that have not adopted a “test and treat” policy are
needed to evaluate whether programs have achieved
their coverage target based on their recommended ART
initiation policy.
The ALPHA network (The Analyzing Longitudinal
Population-based HIV/AIDS data on Africa) has developed
an alternative model which requires only age-specific mor-
tality patterns of PLHIV to predict ART need for different
CD4 initiation criteria [20].
The model estimates the proportion in need of ART,
by sex and age group, among PLHIV who would be
expected to die within a pre-specified period in the
absence of ART. The pre-specified period is equivalent
to CD4 count cut-offs; thus the model can be adopted
for different countries or local policy guidelines of ART
eligibility. The optimal period from ART initiation to
death is an important parameter in deciding when to
start ART in most policy guidelines. The model takes
into account age-related disease progression and cumu-
lative estimated treatment need due to the improved
survival of those accessing treatment [21]. Model esti-
mates can then be applied on national or sub-national
populations of PLHIV to estimate the number in need of
ART. Estimates of the number of HIV-positive individ-
uals can be derived from representative HIV prevalence
surveys available in many resource-limited countries.
The additional advantage of the ALPHA model is its
capability to estimate the proportion of HIV individuals
in need of pre-ART care. Pre-ART care coverage is the
ratio of PLHIV who are not eligible for ART (CD4
count > policy recommendation), over all PLHIV in the
population. People on pre-ART care are enrolled for
CD4 count monitoring, prophylaxis, nutritional advice
and counseling. Early enrolment to pre-ART care is a
gateway to appropriate timing of ART initiation, there-
fore pre-ART care coverage is an important indicator of
the future success of national and regional ART program
implementation [22,23].
Table 1 Maximum age-specific proportions of HIV-positive
people’s need of ART in 2005–2010 using CD4 criteria
of < 200
2005 2006 2007 2008 2009 2010
Age 0 1 2 3 4 5
15 - 19 0.094 0.111 0.124 0.131 0.135 0.136
20 - 24 0.151 0.190 0.224 0.253 0.277 0.296
25 - 29 0.192 0.243 0.288 0.328 0.364 0.395
30 - 34 0.226 0.285 0.338 0.386 0.428 0.465
35 - 39 0.255 0.321 0.380 0.432 0.478 0.520
40 - 44 0.280 0.352 0.415 0.471 0.521 0.564
45 - 49 0.303 0.380 0.447 0.505 0.556 0.602
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coverage by age and sex in the rural Rufiji district in
Tanzania in line with the WHO guideline of 2006 and
2010 and with PLHIV using routinely aggregated
patient-level cohort data from 2006–2010.
Methods
District population characteristics
Rufiji is one of six administrative districts in the Pwani
Region of Tanzania approximately 180 km south of Dar
es Salaam, the country’s largest city. The district has a
population of approximately 217000 according to the
most recent national census conducted in 2012 [24].
The regional literacy rate in the district is 73.6 and the
majority of the population works in agriculture. Between
2008 and 2012, HIV prevalence among males in the re-
gion decreased from 4.2 to 2.1, increased among females
from 8.4 to 9.2 and decreased in the general population
from 6.7 to 5.9 according to the Tanzania HIV/AIDS
and Malaria Indicator Survey (THMIS) of 2007/08 and
2012 [25,26]. There is considerable stigma directed at
people living with HIV and those on ART in the district
as described in detail in previous studies [27,28].
Number of PLHIV in need of treatment
The ALPHA model estimation process is described in
Figure 1. It begins with estimation of parameters de-
scribing age-specific mortality patterns of PLHIV in the
absence of treatment from Weibul model. P(a) is sur-
vival probabilities for HIV-positive individuals from
15 years of age to age a years. Parameters describing
age-specific mortality patterns are: overall mortality level
(λ); and patterns of increase in mortality with age (ϕ).
The model parameters can be obtained from studies
conducted in settings where the ART estimation is being
conducted or borrowed/adopted from studies that haveFigure 1 Graphical summary of ALPHA model for estimating ART neebeen conducted in places with comparable population
characteristics. P(a) is then applied to estimate D(a, n, 0)
which is the probability of dying in the next n years for
an HIV-infected person aged a in a population where
ART is not yet available (i.e. available for 0 years). The
value of n can be conceptualized as the mean time from
the ideal start of treatment to expected AIDS death in
the absence of treatment. This value is equivalent to the
minimum level of CD4 count for AIDS patients to start
ART. In this article, we chose values of n = 3 and n =
6 years which are equivalent to a CD4 count of 200 and
350 used as the threshold in the national ART programs.
Further details on estimated values for different CD4
count levels can be found elsewhere in the literature
[17,18,29,30].
We adopted parameter estimates λ and ϕ from HIV
cohort study from the Kisesa district in Tanzania were
the value of λ = 0.0094 and ϕ = 1.59 were estimated. The
methodology on how these parameters were estimated
has been fully described in a previous paper [20,31].
District ART programs that enroll individuals who are
expected to die in the next n years in the absence ofd.
Table 2 Maximum age-specific proportions of HIV-positive
people’s need of ART in 2005–2010 using CD4 criteria
of < 350
2005 2006 2007 2008 2009 2010
Age 0 1 2 3 4 5
15 - 19 0.212 0.227 0.238 0.244 0.247 0.248
20 - 24 0.301 0.333 0.361 0.384 0.404 0.420
25 - 29 0.364 0.404 0.440 0.471 0.499 0.524
30 - 34 0.414 0.459 0.499 0.535 0.567 0.595
35 - 39 0.456 0.505 0.547 0.585 0.619 0.649
40 - 44 0.492 0.543 0.587 0.627 0.662 0.692
45 - 49 0.523 0.576 0.621 0.661 0.697 0.727
Levira et al. BMC Public Health  (2015) 15:195 Page 4 of 12treatment, need to enroll additional people every calen-
dar year as PLHIV cohorts age and more people enter
into the high death risk period y years following the start
of ART. The proportion of PLHIV currently aged a who
will need treatment is defined by D(a, n, y). The final
output of the model T(y) is the proportion of HIV-
positive individuals in need of treatment in year y
following the introduction of an ART program who are
expected to die in n years in the absence of treatment.
Age-specific proportions needing ART for individuals
aged 15 to 49 years for CD4 initiating criteria of 200
and 350 or less produced by ALPHA model are shown
in Tables 1 and 2 respectively.
To calculate the actual number needing treatment, the
proportion of PLHIV who will need ART is applied to
the numerical age distribution of HIV-positive individ-
uals (H(y)) identified in the population in a particular
year, allowing for the number of years y that have passed
since the start of ART availability. The overall needs for
ART are calculated by summing the number in need of
treatment across age groups. The difference between the
number of all PLHIV and the number of PLHIV in need
of treatment with specific CD4 counts criteria gives the
number in need of pre-ART care. Transitions from pre-
ART care to ART for patients started treatment are de-
scribed in the cascade transition figure.Table 3 PLHIV enrolled on ART by age, sex and calendar year
Both Female
Age 2006 2007 2008 2009 2010 2006 2007
15-19 2 2 3 4 3 2 2
20-24 5 16 26 33 40 4 11
25-29 17 58 77 105 123 16 52
30-34 35 92 153 191 237 25 69
35-39 49 102 142 201 244 33 69
40-44 29 69 105 135 193 20 40
45-49 13 30 46 58 75 7 16
Total 148 370 552 725 914 106 259Number of people living with HIV in the population
The total annual number of people living with HIV in
the population was obtained as a product of the an-
nual district population and HIV prevalence. District
age and sex population from 2006 to 2010 were esti-
mated from the projection of 2002 national census
data.
National average age- and sex-specific HIV prevalence
estimates from the Tanzania HIV/AIDS indicator survey
of 2007/2008 for adults aged 15–49 years were used
[26]. Country estimates were considered because district
estimates are not available, regional estimate do not in-
clude age- and sex-disaggregated data and district preva-
lence data are facility-based with a risk of over estimating
prevalence. There were few changes in HIV prevalence
between 2007 and 2012 in Tanzania (http://www.
dhsprogram.com/). The HIV prevalence for individuals
aged 15–49 in the 2007/2008 survey was 5.8 while the
most recent survey, conducted in 2012, reported a
prevalence of 5.3 [25].
Data collection
Number of HIV-infected individuals on treatment
Patient data for this analysis were derived from the
CTCs that provided ART services in the Rufiji district at
the time of data collection. In 2005, an ART scale-up
pilot was performed at Mchukwi Mission Hospital in
Rufiji. By 2010, the ART program had been extended to
Utete District Hospital (2006), Nyaminywili Health Centre
(2009), Nyamisati Dispensary (2009), Ikwiriri Health
Centre (2010) and Kibiti Health Centre (2010). In 2010,
the Pwani region, where Rufiji is situated, had 28 CTC
units, 23,212 patients were enrolled in care and 9,985 had
commenced ART [32].
Patient data were retrieved from care and treatment
registries. The care register keeps records of basic infor-
mation on clients who have not yet started ART. Once a
patient starts on ART, they are transferred to the ART
treatment register. The patient data are kept across
registries and longitudinally identified using the 7-digitMale
2008 2009 2010 2006 2007 2008 2009 2010
3 4 3 0 0 0 0 0
22 29 36 1 4 4 4 4
68 91 103 1 6 9 14 19
117 148 184 10 23 36 43 53
96 137 170 16 34 46 64 75
60 78 126 10 29 45 57 67
23 29 39 5 14 23 29 36
390 514 661 42 110 163 211 253
Table 4 PLHIV enrolled on pre-ART care by age, sex and calendar year
Both Female Male
Age 2006 2007 2008 2009 2010 2006 2007 2008 2009 2010 2006 2007 2008 2009 2010
15-19 3 4 9 8 6 2 4 9 8 6 1 0 0 0 1
20-24 8 26 34 55 71 5 21 29 49 64 2 5 4 6 7
25-29 24 45 72 126 155 20 42 64 103 130 4 3 9 23 25
30-34 43 57 128 172 213 35 45 99 133 159 7 12 30 39 54
35-39 33 65 97 155 200 22 43 66 98 137 11 22 31 56 63
40-44 21 45 72 91 121 14 26 46 53 76 7 19 26 39 45
45-49 8 13 24 39 52 5 9 14 22 30 2 5 10 17 22
Total 139 251 427 638 819 105 190 327 466 602 34 66 110 180 218
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the CTC database was done from September 2009 to
January 2011. Stata software version 12.0 (Stata Corp,
College Station, TX) was used to organize and generate
descriptive statistics of patients registered for care and
treatment.Table 5 Number of HIV-positive people’s need of ART in
2005–2010 using of all HIV+ individual
ALL
2006 2007 2008 2009 2010
15 - 19 185 186 187 189 190
20 - 24 646 651 655 660 665
25 - 29 915 921 928 934 941
30 - 34 1162 1171 1179 1187 1195
35 - 39 1059 1066 1074 1081 1089
40 - 44 657 662 666 671 676
45 - 49 429 432 435 439 442
Total 5053 5089 5124 5161 5197
FEMALE
15 - 19 119 120 121 122 123
20 - 24 550 553 557 561 565
25 - 29 624 628 633 637 641
30 - 34 747 753 758 763 769
35 - 39 539 543 547 551 555
40 - 44 350 352 355 357 360
45 - 49 231 233 234 236 237
Total 3160 3182 3205 3227 3250
MALE
15 - 19 67 67 66 66 65
20 - 24 113 112 111 110 110
25 - 29 327 325 323 321 318
30 - 34 418 415 412 410 407
35 - 39 454 451 448 445 442
40 - 44 228 226 224 223 221
45 - 49 154 153 152 151 150
Total 1762 1749 1737 1725 1713Ethics statement
The national ethics committee of Tanzania (Medical
Research Coordinating Committee) and the Tanzania
Commission for Science and Technology (COSTECH)
approved the study with approval reference number
NIMR/HQ/R.8a/VolIX/609.Table 6 Number of HIV-positive people’s need of ART in
2005–2010 using CD4 criteria of < 350
ALL
2006 2007 2008 2009 2010
15 - 19 42 44 46 47 47
20 - 24 215 235 252 267 279
25 - 29 370 405 437 466 493
30 - 34 534 585 631 673 712
35 - 39 534 584 629 670 707
40 - 44 357 389 418 444 468
45 - 49 247 269 288 305 321
Total 2299 2509 2700 2872 3027
FEMALE
15 - 19 27 29 29 30 30
20 - 24 183 200 214 227 237
25 - 29 252 276 298 318 336
30 - 34 343 376 406 433 458
35 - 39 272 297 320 341 360
40 - 44 190 207 222 236 249
45 - 49 133 145 155 164 173
Total 1400 1529 1645 1750 1844
MALE
15 - 19 15 16 16 16 17
20 - 24 36 39 42 44 46
25 - 29 116 127 138 147 155
30 - 34 190 208 224 239 253
35 - 39 262 287 309 329 347
40 - 44 165 179 193 205 216
45 - 49 116 126 136 144 151
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PLHIV enrolled on district pre-ART care and ART
programs
A total of 139 and 148 HIV-positive individuals were en-
rolled on pre-ART care and ART programs respectively
in 2006 following a pilot study in 2005. By 2010, a total
of 819 and 914 individuals were registered in pre-ART
care and ART programs, representing a six-fold increase
over a four-year period. There were more people on
ART than in pre-ART care and more females than males
in both pre-ART care and ART programs. Details of the
distribution by year, age and sex are shown in Tables 3
and 4.treatment treatment
Figure 2 Numbers of PLHIV in the cascade of care and
treatment in 2010.Transition from pre-ART to ART
We observe in cumulative a total of 1059 (38%) indi-
vidual’s transition from pre-ART to ART cascade
among 2758 individuals started pre-ART in the study
area. The transition took on average 3 months and longerTable 7 Number of HIV-positive people’s need of ART in
2005–2010 using CD4 criteria of < 200
ALL
2006 2007 2008 2009 2010
15 - 19 21 23 25 25 26
20 - 24 123 146 166 183 197
25 - 29 222 265 305 340 372
30 - 34 332 396 454 508 556
35 - 39 340 405 464 517 566
40 - 44 231 275 314 349 381
45 - 49 163 193 220 244 266
Total 1431 1703 1947 2166 2363
FEMALE
15 - 19 13 15 16 16 17
20 - 24 104 124 141 155 167
25 - 29 152 181 208 232 254
30 - 34 213 255 292 326 358
35 - 39 173 206 236 264 288
40 - 44 123 146 167 186 203
45 - 49 88 104 118 131 143
Total 866 1031 1178 1311 1429
MALE
15 - 19 7 16 9 9 9
20 - 24 20 58 27 30 33
25 - 29 70 198 96 107 117
30 - 34 118 322 162 181 198
35 - 39 167 429 228 254 278
40 - 44 107 256 145 161 176
45 - 49 77 184 104 115 125
Total 566 1463 770 857 936(3.7 months) for those initiated pre-ART care at an earlier
stage of the disease (WHO stage 1) compared to those
started at late stage (WHO stage 4) (2.3 months).PLHIV needing pre-ART care and ART
The number of adults living with HIV needing ART irre-
spective of CD4 counts, CD4 of 350 and 200 between
2006 and 2010 are presented in Tables 5, 6 and 7 re-
spectively. Compared to providing ART to all 5197
PLHIV in the district in 2010, the district could aim to
provide ART to 3027 (42% less) if 2010 guidelines were
in place and 2363 (54% less) with CD4 criteria of 200.
The district provided pre-ART care to 819 and ART to
914 PLHIV in 2010 (Figure 2).Annual ART coverage by sex
The overall ART coverage among PLHIV increased from
2.9% in 2006 to 17.6% in 2010 (Table 8). In 2010, the
ART coverage among PLHIV was 20% for women and
14.8% for men. The adult ART coverage was 21.4% and
35.9% in 2010 with reference to CD4 criteria of 350 for
males and females respectively. With reference to CD4
criteria of 200, adult ART coverage was 27.1% and 46.2%
for males and females respectively. Coverage was con-
sistently higher among women than among men over
the study period.Table 8 ART coverage by sex, CD4 threshold and year
Both Male Female
< 200 <350 HIV+ <200 <350 HIV+ <200 <350 HIV+
2006 10.4 6.5 2.9 7.5 4.7 2.4 12.2 7.6 3.4
2007 21.7 14.7 7.3 7.6 11.2 6.3 25.2 17.0 8.2
2008 28.4 20.5 10.8 21.1 15.4 9.4 33.1 23.7 12.2
2009 33.5 25.2 14.0 24.6 18.7 12.2 39.2 29.4 15.9
2010 38.7 30.2 17.6 27.1 21.4 14.8 46.2 35.9 20.3
Table 9 Pre-ART care coverage by sex, CD4 threshold and year
Both Male Female
<200 <350 HIV+ < 200 < 350 HIV+ < 200 < 350 HIV+
2006 3.8 5.0 0 2.6 3.6 0 4.6 6.0 0
2007 7.4 9.7 0 2.4 7.6 0 8.8 11.5 0
2008 13.5 17.6 0 9.5 13.7 0 16.1 20.9 0
2009 21.3 27.9 0 16.6 24.2 0 24.3 31.5 0
2010 28.9 37.7 0 21.4 21.3 0 33.0 43.6 0
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The adult pre-ART care coverage for PLHIV of CD4 < 350
increased from 5% in 2006 to 37.7% in 2010. Similar to
ART coverage, the pre-ART care coverage was almost
twice as high among females compared to males over the
study period (Table 9). The pre-ART care coverage for
PLHIV with CD4 < 350 was higher than for PLHIV with
CD4 < 200 since the majority of those considered in need
of pre-ART care were shifted to those who needed ART.
In the “test and treat” policy scenario, all PLHIV would be
eligible for ART, which is why the pre-ART care coverage
is zero.
Annual age- and sex-specific pre-ART care and ART
coverage
ART coverage increased across all age groups and sexes
between 2006 and 2010 (Figure 3 for CD4 < 200 in
2010). ART coverage among PLHIV was very low among
young people aged 15 to 24 and in particular among
men (Table 10). In 2010, treatment coverage amongFigure 3 Percent in need of care and treatment by age group and caPLHIV was 1.7 and 5.9% for individuals aged 15–19 and
20–24 respectively. High coverage was observed among
individuals aged 40–44 where females and males had
coverage estimate of 35% and 30.3% respectively. ART
coverage was zero among 15–19 year-olds and only 3.4%
and 6% in young men in the groups 20–24 and 25–30
respectively in 2010.
The distributions of pre-ART care coverage were simi-
lar to the pattern of ART coverage for all age groups and
both sexes. As opposed to most high-income settings,
pre-ART care coverage estimates were slightly lower
than the treatment coverage values for all age groups
and both sexes. More details on the distribution of pre-
ART care coverage by sex, age and calendar year are
given in Table 11.
ART coverage forecast
Annual ART coverage was observed to increase in linear
trends over the analysis period. Linear forecast of ART
coverage at CD4 count < 350 was estimated at 42, 48lendar year for CD4 < 200 criteria.
Table 10 ART coverage by sex, age and CD4 threshold
CD4 < 200
Both Female Male
Age 2006 2007 2008 2009 2010 2006 2007 2008 2009 2010 2006 2007 2008 2009 2010
15-19 8.9 10.2 10.8 13.9 12.7 13.8 15.8 16.7 21.5 19.7 0.0 0.0 0.0 0.0 0.0
20-24 3.9 10.7 15.6 17.9 20.1 3.7 9.0 15.7 18.5 21.4 4.9 7.8 13.7 13.0 11.3
25-29 7.5 21.9 25.4 30.8 33.0 10.4 28.6 32.9 39.1 40.8 1.3 3.2 9.5 13.0 16.4
30-34 10.4 23.3 33.7 37.6 42.6 11.6 27.2 40.2 45.4 51.3 8.3 7.1 22.3 23.8 26.9
35-39 14.3 25.3 30.6 38.8 43.2 18.9 33.3 40.8 51.9 58.9 9.6 7.9 20.1 25.2 26.8
40-44 12.7 25.2 33.4 38.6 50.6 16.0 27.2 36.1 41.8 62.0 9.0 11.5 30.9 35.4 38.1
45-49 7.7 15.6 20.9 23.6 28.1 8.5 15.7 19.2 22.0 27.3 6.7 7.5 22.5 25.0 28.5
CD4 < 350
2006 2007 2008 2009 2010 2006 2007 2008 2009 2010 2006 2007 2008 2009 2010
15-19 4.4 5.3 5.8 7.6 7.0 6.8 8.2 8.9 11.7 10.8 0.0 0.0 0.0 0.0 0.0
20-24 2.2 6.6 10.3 12.2 14.2 2.1 5.6 10.3 12.7 15.1 2.8 11.5 9.0 8.9 8.0
25-29 4.5 14.3 17.7 22.4 24.9 6.3 18.8 22.9 28.5 30.8 0.8 4.9 6.6 9.5 12.4
30-34 6.5 15.8 24.3 28.4 33.3 7.2 18.4 28.9 34.2 40.1 5.1 11.0 16.0 18.0 21.0
35-39 9.1 17.5 22.6 30.0 34.6 12.0 23.1 30.1 40.1 47.2 6.1 11.7 14.8 19.5 21.4
40-44 8.2 17.8 25.1 30.3 41.2 10.4 19.2 27.1 32.9 50.5 5.8 16.4 23.2 27.8 31.0
45-49 5.1 11.2 16.0 18.8 23.3 5.6 11.3 14.7 17.6 22.6 4.4 10.9 17.2 20.0 23.6
All HIV +
2006 2007 2008 2009 2010 2006 2007 2008 2009 2010 2006 2007 2008 2009 2010
15-19 1.0 1.3 1.4 1.9 1.7 1.5 2.0 2.2 2.9 2.7 0.0 0.0 0.0 0.0 0.0
20-24 0.7 2.4 3.9 4.9 5.9 0.7 2.0 4.0 5.1 6.3 0.9 4.0 3.4 3.6 3.4
25-29 1.8 6.3 8.3 11.2 13.0 2.5 8.2 10.8 14.2 16.1 0.3 1.9 2.8 4.3 6.0
30-34 3.0 7.9 13.0 16.1 19.8 3.3 9.2 15.5 19.4 23.9 2.3 5.5 8.7 10.5 13.1
35-39 4.6 9.6 13.2 18.6 22.5 6.1 12.6 17.6 24.8 30.6 3.5 7.5 10.2 14.4 16.9
40-44 4.5 10.4 15.8 20.1 28.5 5.6 11.3 17.0 21.8 35.0 4.2 13.0 19.9 25.6 30.3
45-49 2.9 7.0 10.6 13.1 16.9 3.2 7.0 9.7 12.2 16.4 3.3 9.0 15.3 19.0 23.8
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ART coverage among PLHIV was forecast to reach 25,
28 and 32% in 2011, 2012 and 2013 respectively.
Discussion
Age- and sex-specific ART coverage are essential in
evaluating progress and program implementation in the
district. ART is not only relevant in treating AIDS
patient but implemented as prevention strategy (TasP).
We utilized district care and treatment data to estimate
pre-ART care and ART coverage in a rural district of
Tanzania. We provided age- and sex-disaggregated esti-
mates of ART coverage to give district program man-
agers a broader understanding of the coverage gap so
that they could make informed decisions on resource
allocation. National estimates of ART coverage are rou-
tinely reported separately for children (<15 years) and
adults (15 years and above) which may be slightly less
comparable to the coverage reported in this analysis
(15–49 years). The district and national comparisons inthis research may provide insights into trends and cover-
age levels and must be interpreted with caution. Our an-
nual analysis of ART coverage in the rural district of
Rufiji in Tanzania between 2006 and 2010 showed slow
progress in scaling up and in reaching PLHIV with ART.
Overall ART coverage among adult PLHIV increased
from 3 to 18% while coverage based on CD4 criteria of
< 350 increased from 6 to 30% between 2006 and 2010.
Using ART eligibility that was operational during the
study period (CD4 < 200), coverage increased from 10 to
38% between 2006 to 2010. The national estimate re-
ported by WHO in 2009 was 32%, slightly higher than
the estimated 25% in the district in the same year. Using
the 2010 WHO guideline, the ART coverage forecast in
the district reached 48 and 54% where the national esti-
mate was 40 and 68% in 2011 and 2012 respectively. In
2013, WHO estimated ART coverage at 41% for adults
PLHIV in Tanzania while projected district ART cover-
age for PLHIV was 32%, substantially lower than the na-
tional estimate. The findings from the analysis provide
Table 11 Pre-ART care coverage by sex, age and CD4 threshold
CD4 < 200x
Both Female Male
Age 2006 2007 2008 2009 2010 2006 2007 2008 2009 2010 2006 2007 2008 2009 2010
15-19 1.8 2.7 5.7 4.8 3.8 1.8 4.0 8.6 7.2 5.4 1.7 0.2 0.3 0.3 0.9
20-24 1.5 5.1 6.9 11.5 15.2 1.2 4.9 7.1 12.1 16.1 2.6 2.3 5.4 7.3 9.6
25-29 3.5 6.8 11.6 21.2 27.3 4.3 9.3 15.0 25.4 33.5 1.8 0.7 4.5 12.4 14.1
30-34 5.2 7.3 17.7 25.3 33.3 6.6 9.0 21.2 30.5 38.7 2.5 1.9 11.5 16.1 23.8
35-39 4.6 9.9 15.9 27.4 38.2 6.0 12.8 21.2 34.2 51.3 3.0 3.1 10.4 20.3 24.6
40-44 4.9 11.7 20.4 28.4 41.1 6.3 12.7 24.4 30.8 48.5 3.3 5.3 16.1 26.0 33.2
45-49 2.8 5.6 11.0 20.1 29.5 3.7 6.9 12.3 21.0 32.0 1.8 2.0 9.5 18.6 26.2
CD4 < 350
2006 2007 2008 2009 2010 2006 2007 2008 2009 2010 2006 2007 2008 2009 2010
15-19 2.1 3.1 6.5 5.5 4.4 2.1 4.6 9.8 8.3 6.2 1.9 0.4 0.4 0.4 1.1
20-24 1.8 6.2 8.4 14.0 18.5 1.5 6.0 8.6 14.7 19.5 3.0 6.3 6.4 8.8 11.7
25-29 4.5 8.7 14.8 26.9 34.7 5.5 11.8 19.0 32.2 42.6 2.0 1.8 5.2 14.5 16.7
30-34 6.8 9.7 23.4 33.5 44.1 8.8 11.9 28.0 40.4 51.1 3.3 5.8 15.4 21.9 32.9
35-39 6.2 13.5 21.8 37.6 52.4 8.3 17.6 29.1 46.9 70.3 4.8 10.8 16.8 33.2 40.9
40-44 6.9 16.6 28.9 40.2 58.3 8.9 18.0 34.6 43.7 68.8 6.3 20.4 31.3 51.2 66.3
45-49 4.2 8.2 16.1 29.3 43.1 5.5 10.0 17.9 30.7 46.7 3.4 8.0 18.6 37.1 53.0
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operational target of reaching PLHIV with a CD4 count
< 200 and universal coverage.
Disaggregated analysis of ART coverage provides evi-
dence that treatment-seeking behavior is driven by aging
and sex. Results suggest that more than twice as many
women compared to men were enrolled in ART. Women
are generally diagnosed earlier with HIV because of HIV
testing services offered during antenatal care visits [33].
ART coverage was consistently lower for males and young




























Figure 4 Annual estimate and forecast of ART coverage at CD4 350 aamong young people aged 15 to 24 and men in particular
were recorded in this study. While the overall ART cover-
age was 18% in 2010, coverage among females aged 35–44
was above 30% and below 4% among young males under
the age of 25. This is a cause for concern, given that men
and women aged 15–24 years accounted for 22% of all
new adult HIV infections in 2011, and this is the group
least likely to know their HIV status and most likely to be
sexually active, have multiple partners and reproduce
[34,35]. An HIV testing study conducted in 2011 for sub-
Saharan Africa showed that only 15% and 10% of youngy = 5.79x + 2.05
R² = 0.986
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tested and had their HIV status confirmed [36]. In 2012,
the HIV prevalence was estimated at 3.4% among women
and 1.4% among men aged 15–24 years in Tanzania
[32,37].
Early enrolment to pre-ART care is a gateway to
appropriate timing of ART initiation and pre-ART care
coverage is therefore an important indicator of the
future success of national and regional ART program
implementation. The fact that the majority who start on
ART in Tanzania do so at advanced stage of AIDS is
likely to be the primary contributor to high attrition and
mortality rates in the first year of the ART program [38].
Loss to follow-up (up to 36%) and high mortality (up to
15%) have been observed in the past three years follow-
ing ART initiation in Tanzania [38].
Slow progress was made in the proportion of HIV-
positive individuals in pre-ART care. Coverage was ob-
served to increase from 5% in 2006 to 38% in 2010 under
CD4 eligibility of < 350. The distribution in terms of age
and sex was similar to ART coverage characterized by low
coverage for young people and men in particular.
Scaling up ART coverage to 80% of PLHIV by 2015
entails increasing the number of people initiating ART
every year while keeping those already started on treat-
ment adherent to ART. Further, decentralizing service
delivery to primary health care facilities and reaching the
young population with counseling and testing services
are key to expanding coverage. The low ART coverage in
this rural Tanzanian district demonstrates the challenge
in meeting global targets and calls for an adjustment of
district pre-ART care and ART programs in order to fit
local realities and priorities. The current financial con-
text and severe lack of human resources are particularly
challenging [37,39].
Coverage estimates depend considerably on an accur-
ate estimation of the number of PLHIV in surveys and a
comprehensive information system to keep track of
those enrolled on ART. HIV prevalence surveys in
Tanzania are often confined to individuals aged 15 to
49 years and therefore the numbers of PLHIV among
children younger than 15 and adults older than 50 years
are not known for certain. As a result, this study ex-
cludes coverage estimation for children and elderly. Due
to a lack of reliable data on HIV prevalence in the dis-
trict, we used national estimates of age- and sex-specific
HIV prevalence to calculated the number of PLHIV, and
thus run the risk of over-estimation if the national aver-
age is far from the true prevalence in the study area.
Our basic model assumptions could bias the results. If a
different survival assumption had been applied (or eligi-
bility for treatment set at a higher CD4 count, which is
currently indeed the case in global guidelines), the pro-
portion in need of treatment would be higher than thecurrent estimates. The second model assumption is that
there is no sex difference in mortality. This is less likely
to be violated based on existing empirical data, but a
higher overall mortality level for one sex will lead to a
higher treatment need across all age groups. To estimate
the cumulative number in need of treatment year by
year, the model assumes that treatment needs for prior
years have been fully satisfied, thus estimating maximum
HIV care and ART coverage. Based on this assumption,
the real coverage may be slightly lower if substantial
proportion of PLHIV is not enrolled every year. There is
a reduced version of the model which estimates reduced
needs (minimum need) taking into consideration pro-
gram success in enrolling all HIV-positive individuals
[21]. This study addresses priority areas that could assist
policymakers and implementers to expand access to pre-
ART care and ART beyond currently achieved targets in
particular for young people aged 15–24 years and for
men. This study has shown that behind low treatment
coverage is very low pre-ART care coverage, a factor
which is an important gateway to ART treatment and a
better treatment outcome. A balanced approach should
address both the recruitment of new eligible individuals
to pre-ART care and ART as well as the successful reten-
tion of those already on ART in the program.Conclusion
ART coverage in the Rufiji district in rural Tanzania is
unevenly distributed and far from the universal coverage
target of 80%, in particular among young men. Con-
nected to the low ART coverage is the low pre-ART care
coverage observed in this study. Taking the most recent
WHO estimate of 2013 into consideration, there has
been little progress in keeping up with ART needs since
2010. Low pre-ART care coverage may be highly associ-
ated with low testing rates and stigma towards individuals
with AIDS as observed elsewhere in Tanzania. Although
attrition analysis was not the aim of this study, we
observed a substantial proportion of drop-out in both pre-
ART care and ART programs which also may have
contributed to the observed low coverage. To strive for
universal coverage, both the recruitment of new eligible
individuals to pre-ART and ART as well as the successful
retention of those already on ART in the program need to
be prioritized.Abbreviations
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